drugset / Trial / NCT04123626

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

NCT04123626 ↗

Phase 1/2 Active not recruiting 11 enrolled ProQR Therapeutics
RandomizedSequentialTriple-blindTreatment

Summary

This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. Single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.

Timeline

Start
2019-10-07
Primary completion
2022-06-07
Completion
2022-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject QR-1123 Antisense oligonucleotide — Intravitreal